Why CGRP Drugs Became First Line for Migraine Prevention

The short answer

In March 2024, the American Headache Society published a position statement in Headache: The Journal of Head and Face Pain declaring that calcitonin gene-related peptide (CGRP)-targeting therapies are a first-line option for migraine prevention. The important word is first-line: the society concluded that patients no longer need to fail older oral preventives before starting a CGRP drug. That judgment rested on more than a decade of clinical-trial data and real-world experience since 2018, which the society summarized as showing these medicines are effective, well tolerated, and safe over the long term. This article explains what changed and what evidence supported it. It is educational and not medical advice.

What the position statement actually says

The statement, authored by Charles, Digre, Goadsby, Robbins, and Hershey for the American Headache Society and published in Headache on March 11, 2024, updates earlier guidance that had treated CGRP therapies as a later-line choice. The core recommendation is that CGRP-targeting treatments should be considered first-line alongside the other established first-line options, "without a requirement for prior failure of other classes of migraine preventive treatment."

That phrase targets a specific practice. For years, coverage rules and treatment habits followed a step-therapy logic: try older, cheaper drugs first, and reserve the newer CGRP medicines for people who had already failed two or more of them. The position statement argues the accumulated evidence no longer justifies that sequence as a blanket rule.

Two drug classes fall under the CGRP umbrella. The first is the monoclonal antibodies that block CGRP or its receptor, given by injection or infusion: erenumab, fremanezumab, galcanezumab, and eptinezumab. The second is the small-molecule CGRP receptor antagonists, or gepants, taken by mouth, with rimegepant and atogepant carrying preventive indications. The society emphasizes that these agents are "migraine-specific," meaning they were designed against a pathway central to migraine biology.

Why the CGRP pathway matters

CGRP is a neuropeptide released around the trigeminal system during migraine attacks. It promotes the dilation of cranial blood vessels and the transmission of pain signals, and its levels rise during attacks. Blocking CGRP or its receptor interrupts that cascade. This is the mechanistic contrast the statement draws with older preventives.

Most drugs long used to prevent migraine were developed for other conditions and later found to reduce attack frequency: certain beta-blockers for blood pressure, topiramate and valproate for epilepsy, amitriptyline for depression, and onabotulinumtoxinA for muscle activity. They help many people, but none was built around migraine mechanisms, and each carries a side-effect profile inherited from its original purpose. The CGRP agents were engineered for the disorder itself.

The efficacy, safety, and tolerability case

The society did not claim CGRP drugs are dramatically more effective than every older option in head-to-head attack reduction. Its argument is more about the balance of benefit, tolerability, and safety across a large evidence base.

On efficacy, the AHS reviewed the randomized trials that supported FDA approval across both episodic and chronic migraine, plus real-world cohorts accumulated since the first approvals in 2018. On tolerability, this is where the newer agents distinguish themselves. Older oral preventives frequently falter in practice not because they fail to work but because patients cannot stay on them. Topiramate, for instance, requires slow titration and commonly produces cognitive fog, tingling, and other dose-limiting effects. The position statement points to how poorly older preventives are sustained in ordinary care: it cites commercial-claims data showing adherence to the standard oral options in the range of 17 to 20 percent at one year. In one head-to-head trial it references, far fewer patients stopped a CGRP antibody because of adverse effects than stopped topiramate for the same reason. The direction of that evidence, rather than any single dramatic number, is the tolerability case.

On safety, the CGRP agents lack several liabilities that constrain older drugs, such as the teratogenic and cognitive concerns of some anti-seizure medicines. Their most common adverse effects are comparatively mild: constipation and injection-site reactions for the antibodies, and generally low serious-event rates across the class. Long-term surveillance since 2018 is part of why the society felt confident revising its guidance, though monitoring of any newer therapy continues.

The access argument

The statement is candid that cost is the practical barrier, since CGRP therapies are more expensive per dose than generic oral preventives. Rather than ignore that, the AHS reframes it. The society urges that treatment decisions not be based "solely on the cost of treatment," and asks payers and clinicians to weigh downstream effects: reduced use of acute medications, fewer emergency visits, and gains in work productivity and reduced absenteeism. The logic is that a therapy people actually tolerate and continue can lower total cost of care even when the drug itself costs more.

This is where a position statement does its real work. It is not a coverage mandate and cannot by itself change an insurer's formulary. What it does is give clinicians and patients a professional-society reference to cite when a step-therapy requirement stands between a patient and a treatment the evidence supports as first-line.

How to read this as evidence

A few cautions keep this in proportion. First-line does not mean first-choice for everyone; the statement positions CGRP therapies among first-line options, not above them, and cost, route of administration, pregnancy plans, and individual response all still matter. Adherence and discontinuation figures come from claims and observational data with their own limitations, and a portion of discontinuations reflect people stopping because they improved, not because a drug failed. The strength of the AHS conclusion comes from convergence: trial efficacy, a cleaner tolerability signal, and several years of post-approval safety data pointing the same direction. That is what let a specialty society move a whole drug class from later-line to first-line in a single update.